| __timestamp | Blueprint Medicines Corporation | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 504755000 |
| Thursday, January 1, 2015 | 14456000 | 838526000 |
| Friday, January 1, 2016 | 19218000 | 1177697000 |
| Sunday, January 1, 2017 | 27986000 | 1320433000 |
| Monday, January 1, 2018 | 47928000 | 1556200000 |
| Tuesday, January 1, 2019 | 96388000 | 1834800000 |
| Wednesday, January 1, 2020 | 157743000 | 1346000000 |
| Friday, January 1, 2021 | 195293000 | 1824900000 |
| Saturday, January 1, 2022 | 237374000 | 2115900000 |
| Sunday, January 1, 2023 | 295141000 | 2631300000 |
| Monday, January 1, 2024 | 359272000 | 2954400000 |
Unlocking the unknown
In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Blueprint Medicines Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses surged by over 400%, peaking at approximately $2.63 billion in 2023. In contrast, Blueprint Medicines, a smaller player, saw a staggering increase of over 3,600%, reaching nearly $295 million in the same year. This stark difference highlights Regeneron's established market presence and Blueprint's rapid growth phase. While Regeneron's expenses reflect its expansive operations, Blueprint's rise underscores its aggressive market entry and expansion strategy. These trends offer a window into the strategic priorities and market dynamics of these biotech leaders.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Johnson & Johnson vs Blueprint Medicines Corporation
AstraZeneca PLC and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Sanofi or Blueprint Medicines Corporation: Who Manages SG&A Costs Better?
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Blueprint Medicines Corporation
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Ionis Pharmaceuticals, Inc.
Blueprint Medicines Corporation vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Blueprint Medicines Corporation and Evotec SE: SG&A Spending Patterns Compared